Each tablet contains:
Bromocriptine mesylate                   2.87mg
(eq. to Bromocriptine 2.5 mg) 

Pharmacological properties:
Bromocriptine mesylate is a dopamine receptor agonist which activates post-synaptic dopamine receptors.The dopaminergic neurons modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin  inhibitory factor. Bromocriptine mesylate is a nonhormonal, nonestrogenic agent that inhibits the secretion of prolactin in human. In about 75% of cases of amenorrhea and galactorrhea, Bromocriptine mesylate therapy suppresses the galactorrhea or almost completely and reinitiates normal ovulatory menstrual cycles. In many acromegalic patients, Bromocriptine, mesylate produces a prompt and sustained reduction in circulating levels of serum growth hormone. 

Bromocriptine is absorbed from G I T, Completely metabolized.The major route of excretion is the bile. Almost all (84.6%) of the administered dose is excreted in the feces in 120 hours.                     


- Hyperprolactinemia-associated dysfunctions; including amenorrhea with or without galactorrhea, infertility or hypogonadism, prolactin secreting adenomas.
- Acromegaly - Parkinson's disease as adjunct to L-dopa. 

Contraindications: Uncontrolled hypertension and sensitivity to any ergot alkaloids.

Warnings: Complete evaluation of the pituitary is indicated before treatment with Bromocriptine since hyperprolactinemia with amenorrhea/galactorrhea and infertility has been found in patients with pituitary tumors.
-Usage of the drug for prevention of physiological lactation in patients with uncontrolled hypertension, seizures, myocardial infarction is not recommended.

- Safety and efficacy of Bromocriptine have not been established in patients with renal or hepatic disease.
- Care should be exercised when administering Dopagon with other medications that lower blood pressure.
- Patients not seeking pregnancy or those harboring large adenomas, should be advised to use contraceptive measures, other than oral contraceptives, during treatment with Dopagon.
- Cold sensitive digital vasospasm is observed in some acromegalic patients treated with Dopagon, so fingers must be kept warm.
- Dopagon administration alone or concomitantly with levodopa may cause hallucinations (visual or auditory).
- Dopagon should be administered with caution in patients with history of serious mental disorders (especially psychotic disorders).

Bromocriptine should be withdrawn when pregnancy is diagnosed. Lactation: Bromocriptine mesylate should not be used during lactation in postpartum women. 

Side Effects:
The most common side effects are:  Nausea, vomiting, anorexia, abdominal cramps, hallucinations, headache, dizziness, Constipation, Fatigue, Postural/orthostatic hypotension and confusion.

Dosage and administration: It is recommended that Bromocriptine mesylate be taken with food.  

Hyperprolactinemic states:
The initial dosage is (1.25 mg - 2.5mg) tablet daily. An additional 2.5 mg tablet may be added to the treatment regimen as tolerated every  3-7 days  The therapeutic dosage usually is 5-7.5 mg and ranges from 2.5- 15 mg/day. In order to reduce the likelihood of prolonged exposure to Bromocriptine should unsuspected pregnancy occur.   Acromegaly: 1.25- 2.5mg on retiring (With food) for 3 days. An additional 0.5-1 tablet every 3-7 days. The usual optimal therapeutic dose from 20-30 mg/day and the maximal dosage should not exceed 100 mg/day. Parkinson's disease: 1.25mg-2.5mg twice daily. The safety of Bromocriptine mesylate has not been demonstrated in dosages exceeding 100 mg/day.

Box of 20 tablets